Loyal Valley Capital

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

O-Net Technologies (Group) Limited is an investment holding company based in Shenzhen, China, specializing in the design, manufacture, and sale of optical networking components, modules, and subsystems for high-speed telecommunications and data communications systems. Founded in 2000, O-Net provides a diverse range of optical communication products, including amplifiers, couplers, connectors, and tunable filters, as well as data center solutions. Additionally, the company manufactures industrial application products such as fiber lasers, electronic cigarette accessories, and mobile phone parts. O-Net also engages in the production of automation equipment and offers coating solutions for consumer electronics. The company operates a research and development center in the United States and has a presence in China, Europe, North America, and other Asian countries. Since its listing on the Hong Kong Stock Exchange in 2010, O-Net has established itself as a key player in the high technology sector, particularly in optical networking and automation.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

CARsgen Therapeutics, Ltd. is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapeutics for cancer treatment. Based in Shanghai, China, the company focuses on innovative immunotherapy solutions that harness the body's immune system to target and eliminate cancer cells. CARsgen's CAR-T technology is designed to direct T cells to recognize and attack tumors based on specific cell surface proteins, targeting conditions such as hepatocellular carcinoma (HCC) and lung squamous cell carcinoma, among others. The company has made significant advancements in CAR-T development, including the completion of the world's first dose-ascending injection tests for HCC and exclusive trials for glioblastoma multiforme in China. Through partnerships with notable institutions like the Shanghai Cancer Institute and Shanghai Renji Hospital, CARsgen Therapeutics aims to position itself at the forefront of cancer therapeutics both in China and internationally.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

OBiO Technology is a biotechnology company based in Shanghai that specializes in viral-based gene therapy. It offers comprehensive Contract Research Organization (CRO) services, focusing on the development of gene therapy vectors, gene function research, and drug efficacy studies. The company also provides Contract Development and Manufacturing Organization (CDMO) services, which include process development, testing, and clinical sample GMP production. OBiO Technology supports the research and development of genetic drugs, facilitating advancements in gene therapy through its expertise in both foundational research and practical applications within the biopharmaceutical industry.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers.

Pop Mart designs, produces, and sells pop-culture figure toys based on intellectual properties. It operates an integrated platform covering the designer toy value chain, including acquiring and incubating IPs, creating original concepts, and licensing rights from IP owners. The company collaborates with IP holders to develop and release collectible figures and related products. Originating in China, Pop Mart has expanded to Southeast Asia and North America, and it also diversifies into accessories, building blocks, and theme park operations to broaden revenue. The business focuses on IP-driven toy lines and scalable partnerships to sustain growth.

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Mahua Fun Age, the largest drama agency in China, was founded in 2003 and has produced popular dramas and movies such as "Clown Loves Beauty", "Count of Mountain Wulong", "Dream of those Years", "Xialuo’s trouble", and "Donkey water". With a strong portfolio of over 20 high-quality original shows and intellectual properties, Mahua Fun Age has established a significant presence in the entertainment industry. In 2016 alone, the company organized more than 1,600 tour shows across China, showcasing its creativity and appeal to a wide audience.

NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.

EVE Energy is a China-based battery company focused on research, manufacturing, and sale of consumer, power, and energy storage batteries. Its product portfolio includes lithium primary cells such as lithium thionyl chloride, lithium manganese dioxide, and lithium iron disulfide; lithium ion cells in cylindrical, pouch, and prismatic formats with aluminum shells and polymer variants. The company also develops energy storage systems for home use, telecom backup, micro grids, and industrial needs, and power systems for electric vehicles, buses, and light vehicles. Applications span smart metering, intelligent transportation, security, smart home, oil drilling, GPS, medical devices, and defense, with lithium ion cells used in energy storage and automotive electronics. EVE positions itself as a national high tech enterprise and a leading lithium primary battery producer, especially in lithium thionyl chloride cells. Founded in 2001 and based in Huizhou, it has invested heavily in power storage and embraces automated, information driven manufacturing to serve global customers.

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

Teligene Ltd., established in 2011 and headquartered in Jiangsu, China, is a pharmaceutical research and development company specializing in the creation of small-molecule drugs for oncology. The company's senior management team, experienced in advanced drug development technologies, focuses on researching and developing innovative, targeted anti-tumor drugs with independent intellectual property rights.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

The #1 international kindergarten in Beijing

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Leading financial and insurance technology company in China

Gaosi Education Group is a Chinese educational institution specializing in extracurricular tutoring for middle and primary school students. Founded in December 2009, it is headquartered in Beijing's Haidian District. The group focuses on gifted education, offering tailored courses for students from primary through junior high school. It features personalized one-on-one teaching centers and emphasizes mathematics competitions as a key component of its curriculum. With nearly 10,000 students enrolled, Gaosi Education Group employs around 100 full-time teachers and staff dedicated to teaching and research.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

Pipilu is a company dedicated to providing entertainment content and products specifically designed for children in China. It focuses on producing original publishing materials, movies, animations, and various consumer products. By prioritizing quality in its offerings, Pipilu aims to deliver engaging and entertaining experiences that cater to the interests and needs of young audiences.

Established in 2013, Studio 9 is a leading original animation IP creation company. It has the highest-yield production line of comics and 2D & 3D animation in China. The company has built its IP production committee to further expand the value of its IP in animation, movies and games. It has also successfully created China's first action animation IP " The Outcast ", and hot IPs such as “No”, “Heaven to Earth”, etc.

Beijing Haixue Education Technology Co., Ltd. is a private company based in China that operates the Haixue platform, which focuses on providing employment and career development solutions for students and professionals. The platform leverages a combination of live lectures and high-definition broadcasting to enhance its training offerings. Utilizing artificial intelligence and big data analysis, Haixue creates personalized learning experiences, recommending challenging knowledge points to users. The company specializes in skill training across various fields, including construction, accounting, law, and health, allowing learners to acquire knowledge and experience efficiently. Through its innovative approach, Haixue aims to systematically enhance the workplace value of individuals and groups.

iDreamSky Technology, established in 2009 and headquartered in Shenzhen, China, is a leading digital entertainment platform in the Chinese game publishing market. It specializes in publishing third-party licensed and self-developed games, spanning genres like role-playing, puzzle, and casual competition, to players through various mobile channels and other publishers. As of 2019, its portfolio comprised 60 games. Additionally, iDreamSky offers digital content services, advertising, and other information services. It has collaborated with major clients such as Lenovo, China Telecom, and HTC. In 2011, it launched Skynet, a one-stop solution for game developers to expand and establish their businesses in China, following a seed investment of $2 million from Hwa Xiu Investment Group.

Luogic Thinking is China’s #1 online producer of educational podcasts.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.

China Mercy Health Group is a healthcare organization founded by Liu Xiaocheng, who has significant experience in medical administration, including roles at the Chinese Academy of Medical Sciences and China Union Medical University. The group is primarily focused on enhancing the efficiency of medical institutions in China through a comprehensive hospital management service platform. Its offerings encompass various aspects of hospital operations, including architectural design, management consultancy, training for healthcare professionals, and logistics for medical supplies. By providing these services, China Mercy Health Group aims to create an optimal healthcare environment that improves patient outcomes and supports the healthcare infrastructure in the region.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

Wenzhou Kangning Hospital operates and manages a network of healthcare facilities in China with a focus on psychiatric specialty care and related mental health services. The group runs owned hospitals and offers elderly rehabilitation services and other healthcare-related activities across multiple regions, generating revenue mainly from operating its hospitals and related healthcare businesses. Its services encompass a range of psychiatric care offerings, including gender-specific psychiatry, addiction treatment, geriatric psychiatry, depression and sleep clinics, child and adolescent psychology, as well as teleconsultation. Founded in 1996 and based in Wenzhou, the company aims to expand access to psychiatric care through its network.